Every temperature excursion represents two risks: compromised patient care and significant financial loss. As specialty pharmaceuticals, biologics, cell therapies, and glucagon-like peptide-1 (GLP-1) medications continue to grow, healthcare organizations are discovering that cold-chain management is no longer a niche operational concern. It is a strategic capability.

Pharmacists were an integral part of the global response to the COVID-19 pandemic, supporting access to treatments, testing, and vaccine delivery. The impact on the pharmaceutical cold chain was unlike any other time in history, and the industry as a whole rose to meet the challenge. However, while these therapies are transforming patient outcomes, they are simultaneously placing unprecedented demands on storage, transportation, monitoring, and inventory management systems throughout the healthcare supply chain. Read More >